Europe Is Won Before Launch: the Leadership, Access and Evidence Playbook for Rare Disease Biotech.
)
)
Rare diseases affect an estimated 36 million people across Europe, yet access to life-changing treatments remains one of healthcare's greatest challenges. While advances in genomics, precision medicine and orphan drug development have accelerated innovation, scientific breakthroughs alone are no longer enough to ensure patient access.
Today, success in Europe's rare disease landscape is increasingly determined by the ability to navigate complex health technology assessments (HTA), reimbursement negotiations, evidence requirements and increasingly fragmented access pathways. For biotech and pharmaceutical companies, the challenge is not simply developing innovative therapies, it's securing sustainable patient access across diverse European markets.
Drawing on market data and insights from senior commercial, medical and market access leaders across Europe, this whitepaper explores the strategies, evidence frameworks and leadership capabilities required to successfully launch rare disease therapies and improve outcomes for patients.
Download the whitepaper to discover why, in Europe, rare disease success is won before launch.
- Whitepaper
- Executive Search
)
Dr Sofia Tapanelli specialises in board, C-suite and senior leadership appointments across the healthcare and life sciences sectors, working with organisations throughout EMEA and the United States. She brings extensive experience in executive search, with a particular understanding of the leadership requirements and specialist talent shaping these industries. Prior to joining Venari Partners, Sofia was a key member of the Healthcare practice at Russell Reynolds Associates and previously held the position of Principal at True Search. Her experience advising organisations on senior appointments is underpinned by a distinguished academic career. A published scientist, Sofia completed her PhD in Life Sciences in collaboration with Imperial College London, where she also held a postdoctoral position supported by a Bill & Melinda Gates Foundation grant. Her research focused on malaria, gene editing technologies and infectious diseases. Alongside her scientific work, Sofia co-founded a start-up focused on sustainable, plant-based products, gaining first-hand experience in business development, fundraising and commercial strategy. Combining scientific expertise, entrepreneurial experience and a deep understanding of executive search, she brings a distinctive perspective to leadership appointments across healthcare and life sciences.
View Full Profile)
)
)
)
)
)
